Loading...

We've got a brand new version of Simply Wall St! Try it out

Senhwa Biosciences

GTSM:6492
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
6492
GTSM
NT$5B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

Senhwa Biosciences, Inc., a clinical-stage drug development company, identifies and develops therapies for the treatment of cancer. The last earnings update was 5 days ago. More info.


Add to Portfolio Compare Print
6492 Share Price and Events
7 Day Returns
-0.8%
GTSM:6492
-1%
TW Biotechs
1.4%
TW Market
1 Year Returns
-4.9%
GTSM:6492
-9.6%
TW Biotechs
17.7%
TW Market
6492 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Senhwa Biosciences (6492) -0.8% -4.3% -0.9% -4.9% -62.3% -
TW Biotechs -1% -2.6% -4.5% -9.6% -39.9% -41.4%
TW Market 1.4% 6% 9.8% 17.7% 27.6% 27.7%
1 Year Return vs Industry and Market
  • 6492 outperformed the Biotechs industry which returned -9.6% over the past year.
  • 6492 underperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
6492
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Senhwa Biosciences's competitors could be found in our database.

Value

 Is Senhwa Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Senhwa Biosciences. This is due to cash flow or dividend data being unavailable. The share price is NT$64.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Senhwa Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Senhwa Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:6492 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in TWD NT$-5.50
GTSM:6492 Share Price ** GTSM (2019-11-08) in TWD NT$64.5
Taiwan, Province of China Biotechs Industry PE Ratio Median Figure of 8 Publicly-Listed Biotechs Companies 41.22x
Taiwan, Province of China Market PE Ratio Median Figure of 1,438 Publicly-Listed Companies 16.62x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Senhwa Biosciences.

GTSM:6492 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:6492 Share Price ÷ EPS (both in TWD)

= 64.5 ÷ -5.50

-11.73x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Senhwa Biosciences is loss making, we can't compare its value to the TW Biotechs industry average.
  • Senhwa Biosciences is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does Senhwa Biosciences's expected growth come at a high price?
Raw Data
GTSM:6492 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.73x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Asia Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.61x
Taiwan, Province of China Market PEG Ratio Median Figure of 244 Publicly-Listed Companies 1.14x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Senhwa Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Senhwa Biosciences's assets?
Raw Data
GTSM:6492 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in TWD NT$12.13
GTSM:6492 Share Price * GTSM (2019-11-08) in TWD NT$64.5
Taiwan, Province of China Biotechs Industry PB Ratio Median Figure of 40 Publicly-Listed Biotechs Companies 3.4x
Taiwan, Province of China Market PB Ratio Median Figure of 1,939 Publicly-Listed Companies 1.46x
GTSM:6492 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:6492 Share Price ÷ Book Value per Share (both in TWD)

= 64.5 ÷ 12.13

5.32x

* Primary Listing of Senhwa Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Senhwa Biosciences is overvalued based on assets compared to the TW Biotechs industry average.
X
Value checks
We assess Senhwa Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Senhwa Biosciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Senhwa Biosciences expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-171.1%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Senhwa Biosciences expected to grow at an attractive rate?
  • Unable to compare Senhwa Biosciences's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Senhwa Biosciences's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Senhwa Biosciences's revenues are expected to decrease over the next 1-3 years, this is below the Taiwan, Province of China market average.
Annual Growth Rates Comparison
Raw Data
GTSM:6492 Future Growth Rates Data Sources
Data Point Source Value (per year)
GTSM:6492 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -171.1%
Taiwan, Province of China Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 65.2%
Taiwan, Province of China Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 60.6%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.3%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 7.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:6492 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:6492 Future Estimates Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 0 -485 1
2019-12-31 0 -510 1
2019-11-11
GTSM:6492 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-09-30 0 -393 -410
2019-06-30 1 -396 -416
2019-03-31 1 -415 -451
2018-12-31 1 -374 -376
2018-09-30 1 -347 -394
2018-06-30 0 -381 -416
2018-03-31 0 -346 -354
2017-12-31 -326 -372
2017-09-30 0 -314 -333
2017-06-30 0 -255 -283
2017-03-31 0 -250 -286
2016-12-31 0 -221 -255

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Senhwa Biosciences is high growth as no earnings estimate data is available.
  • Senhwa Biosciences's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:6492 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Senhwa Biosciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6492 Future Estimates Data
Date (Data in TWD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
2019-11-11
GTSM:6492 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-09-30 -5.50
2019-06-30 -5.59
2019-03-31 -6.06
2018-12-31 -5.05
2018-09-30 -5.29
2018-06-30 -5.58
2018-03-31 -4.79
2017-12-31 -5.18
2017-09-30 -4.79
2017-06-30 -4.20
2017-03-31 -4.36
2016-12-31 -3.89

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Senhwa Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Senhwa Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Senhwa Biosciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Senhwa Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Senhwa Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Senhwa Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Senhwa Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Senhwa Biosciences's 1-year growth to the TW Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Senhwa Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Senhwa Biosciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:6492 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 0.40 -410.14 58.26 355.79
2019-06-30 0.55 -415.90 60.61 361.65
2019-03-31 0.70 -450.88 60.60 400.74
2018-12-31 0.73 -375.85 60.12 327.42
2018-09-30 0.53 -393.54 62.70 340.99
2018-06-30 0.33 -415.58 60.79 363.97
2018-03-31 0.13 -354.34 61.74 301.97
2017-12-31 -371.90 60.65 314.74
2017-09-30 0.00 -333.33 61.76 276.62
2017-06-30 0.13 -283.07 59.67 227.63
2017-03-31 0.13 -286.10 54.89 232.12
2016-12-31 0.13 -255.02 51.28 206.86
2016-09-30 0.13 -233.19 42.49 191.43
2016-06-30 -212.18 39.80 176.46
2016-03-31 -193.93 39.87 158.41
2015-12-31 -194.00 39.26 161.76
2015-09-30 2.35 -179.56 36.76 152.08
2015-06-30 4.71 -181.53 35.05 153.12
2015-03-31 14.17 -165.02 34.46 137.73
2014-12-31 23.63 -157.03 36.88 127.87
2014-09-30 31.11 -138.57 33.75 111.57
2014-06-30 38.60 -120.11 30.62 95.26
2014-03-31 32.43 -116.65 21.26 98.56
2013-12-31 26.26 -113.18 11.89 101.85
2012-12-31 -8.03 10.82

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Senhwa Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Senhwa Biosciences has efficiently used its assets last year compared to the TW Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Senhwa Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Senhwa Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Senhwa Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Senhwa Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Senhwa Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Senhwa Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Senhwa Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Senhwa Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Senhwa Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Senhwa Biosciences Company Filings, last reported 1 month ago.

GTSM:6492 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 906.30 0.00 915.58
2019-06-30 984.05 0.00 992.34
2019-03-31 1,075.01 0.00 1,082.89
2018-12-31 1,209.34 0.00 1,229.49
2018-09-30 1,301.00 0.00 1,311.57
2018-06-30 1,383.15 0.00 1,390.28
2018-03-31 1,507.40 0.00 1,496.40
2017-12-31 1,568.06 0.00 1,601.00
2017-09-30 1,677.76 0.00 1,656.20
2017-06-30 1,782.87 0.00 1,772.39
2017-03-31 427.30 0.00 425.27
2016-12-31 511.67 0.00 513.88
2016-09-30 564.77 0.00 552.82
2016-06-30 619.55 0.00 606.42
2016-03-31 730.73 0.00 733.59
2015-12-31 730.73 0.00 733.59
2015-09-30
2015-06-30 812.48 0.00 796.75
2015-03-31 812.48 0.00 796.75
2014-12-31 904.01 0.00 838.94
2014-09-30 904.01 0.00 838.94
2014-06-30 756.29 0.00 760.65
2014-03-31 756.29 0.00 760.65
2013-12-31 812.01 0.00 754.25
2012-12-31 399.33 0.00 399.58
  • Senhwa Biosciences has no debt.
  • Senhwa Biosciences has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Senhwa Biosciences has sufficient cash runway for 2.3 years based on current free cash flow.
  • Senhwa Biosciences has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 20.4% each year.
X
Financial health checks
We assess Senhwa Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Senhwa Biosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Senhwa Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Senhwa Biosciences dividends.
If you bought NT$2,000 of Senhwa Biosciences shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Senhwa Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Senhwa Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:6492 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1337 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

GTSM:6492 Future Dividends Estimate Data
Date (Data in NT$) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2019-11-11

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Senhwa Biosciences has not reported any payouts.
  • Unable to verify if Senhwa Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Senhwa Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Senhwa Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Senhwa Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Senhwa Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Senhwa Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Senhwa Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tai-Sen Soong
CEO Bio

Dr. Tai-Sen Soong, Ph.D. is a Co-Founder of Medtech Tronics, Inc. Dr. Soong serves as the President and Vice Chairman at CDIB BioScience Venture Management. Dr. Soong serves as Chief Executive Officer and President at Senhwa Biosciences, Inc. He also served as Head of Life Science Investment Unit in Overseas Business Department at CDIB since 1999. Prior to joining CDIB, he had also served as the Managing Director at Imagen Venture Holdings. Dr. Soong served as the Director of Taiwan's Development Center for Biotechnology from 1986 to 1995, he established a research and development base for commercial application of biotechnology and promoted Taiwan's biotech industry through product development and technology transfer. Dr. Soong was a Research Specialist at Monsanto Corp. He serves as a Founding Member and Board of Directors of Panlabs Biologics, HenKan Pharmaceuticals, and Medtech Tronics, Inc. He has been Director of CDIB BioScience Venture Management since December 2001. He was a Professor at National University of Singapore. During his service in Singapore, Dr. Soong successfully launched Singapore China Biotechnology Program to introduce scientists from mainland China to assist biotechnology development in Singapore. He received a Ph.D. in Biology from University of Illinois Urbana-Champaign.

CEO Compensation
  • Insufficient data for Tai-Sen to compare compensation growth.
  • Insufficient data for Tai-Sen to establish whether their remuneration is reasonable compared to companies of similar size in Taiwan, Province of China.
Management Team

Tai-Sen Soong

TITLE
CEO & President

Sarah Chang

TITLE
CFO and Head of Finance & Administration

Lucas Chang

TITLE
Vice President and General Counsel
AGE
64
TENURE
2.9 yrs
Board of Directors

Benny Hu

TITLE
Chairman
AGE
71
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess Senhwa Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Senhwa Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Senhwa Biosciences, Inc., a clinical-stage drug development company, identifies and develops therapies for the treatment of cancer. The company is developing CX-4945 that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-5461 AU, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; and CX-5461 CA, which is in phase I clinical trials in patients with solid tumors and breast cancer. It is also developing CX-4945-07, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and PBTC-053, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma. The company was founded in 2012 and is based in New Taipei City, Taiwan.

Details
Name: Senhwa Biosciences, Inc.
6492
Exchange: GTSM
Founded: 2012
NT$4,803,677,490
74,475,620
Website: http://www.senhwabiosciences.com
Address: Senhwa Biosciences, Inc.
No. 225, Peihsin Road,
10th Floor,
New Taipei City,
23143,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 6492 Common Shares Taipei Exchange TW TWD 04. Dec 2014
Number of employees
Current staff
Staff numbers
0
Senhwa Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/11 15:05
End of day share price update: 2019/11/08 00:00
Last estimates confirmation: 2019/10/08
Last earnings filing: 2019/11/06
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.